Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 7, Pages 1421-1427
Publisher
Oxford University Press (OUP)
Online
2015-04-22
DOI
10.1093/annonc/mdv186
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Two Dimensions in Targeting HER2
- (2014) Mark M. Moasser JOURNAL OF CLINICAL ONCOLOGY
- NSCLC and HER2: Between Lights and Shadows
- (2014) Giuseppina Rosaria Rita Ricciardi et al. Journal of Thoracic Oncology
- Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
- (2014) Pasi A Jänne et al. LANCET ONCOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- HER2 and lung cancer
- (2013) Lorenza Landi et al. Expert Review of Anticancer Therapy
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
- (2013) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- HER2 Mutations in Non–Small-Cell Lung Cancer Can Be Continually Targeted
- (2012) Ronan J. Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer
- (2012) Federico Cappuzzo et al. Journal of Thoracic Oncology
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
- (2012) H. Greulich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
- (2011) Chenguang Li et al. Journal of Thoracic Oncology
- Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
- (2011) Kenji Tomizawa et al. LUNG CANCER
- Integration of Molecular Profiling into the Lung Cancer Clinic
- (2009) W. Pao et al. CLINICAL CANCER RESEARCH
- HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
- (2009) S. A. Perera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now